More specifically, chronic administration of sitagliptin reduced both hippocampal APP and Aβ deposition in the transgenic AD mice (117) (Figure 1), whereas in the insulin-resistant rats, it promoted a decrease in plasma insulin, cholesterol, and HDL levels, and ameliorated the HOMA values (an index of insulin resistance) (118). Here, APP is linked to Alzheimer disease.